Shares of the company today closed at Rs 419.90 per scrip on BSE, up 1.10% from its pevious close
New Delhi, Jan 19, 2015 – Biotechnology major Biocon today concluded sale of 10% stake in its research arm Syngene for Rs 380 crore to IVF Trustee Company Private Ltd.
In September, Biocon had announced that Mauritius-based private equity fund Silver Leaf Oak would acquire 10% stake in its research services arm Syngene International for Rs 380 crore from Biocon Research Ltd (BRL), a wholly-owned subsidiary of the Bangalore-based firm.
In a filing to the BSE, Biocon said Silver Leaf Oak has “assigned its rights and obligations for acquisition of 10% stake in Syngene International Ltd to IVF Trustee Company Pvt Ltd”.
Both Silver Leaf Oak and IVF Trustee Company are investment vehicles advised by India Value Fund Advisors (IVF).
“Biocon Research Ltd, a wholly owned subsidiary of the Company has concluded such sale to IVF. Post conclusion of the above, Biocon and BRL jointly hold 85.54% stake in Syngene,” the filing added.
The deal had put the entire valuation of Syngene International Ltd, a wholly-owned subsidiary of Biocon Ltd, at Rs 3,800 crore.
Shares of Biocon Ltd today closed at Rs 419.90 per scrip on BSE, up 1.10% from its pevious close. PTI
New Delhi, November 06, 2024: Arla Foods Ingredients has launched a new whey protein hydrolysate…
By Dr. C N Patil, HOD and Lead Consultant - Medical Oncology & Haemato-Oncology, Aster…
· World's no.1 skincare brand Bepanthen* launches in India, as a solution to tackle India's widespread dry skin…
By Dr. Pavan Yadav, Lead Consultant - Interventional Pulmonology & Lung Transplantation, Aster RV Hospital.…
Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru Winter weather brings a host…
By Dr. Naveen Ganjoo, Senior Consultant - Hepatology & Integrated Liver Care, Aster RV Hospital…